Navigation Links
Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
Date:6/13/2008

NEW HAVEN, Conn., June 13 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that data from a previously conducted Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in elderly patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndromes (MDS) had been presented at the 13th Congress of the European Hematology Association (EHA) at the Bella Center in Copenhagen, Denmark. At the Congress, data were presented in a subset of 26 patients with high-risk MDS by French-American-British (FAB) Group criteria.

The median age of the patients in the subset was 71 years (range of 59-82 years). Twelve patients were diagnosed with refractory anemia with excess blasts (RAEB) and 9 patients were diagnosed with RAEB-t. Five patients were diagnosed with either chronic myelomonocytic leukemias (CMML) (3) or as unknown (2). Fifteen patients had intermediate cytogenetics and 11 had unfavorable cytogenetics. Sixteen of the patients were classified as Intermediate-2 risk by the International Prognostic Scoring System (IPSS) system (1.5-2.0), and 10 were classified as high risk (greater than or equal to 2.5).

Eight of the 26 patients had received prior treatment for their disease. Prior agents used included arsenic trioxide, thalidomide, Ara-C, imatinib mesylate, interferon, amifostine, melphalan, hydroxyurea and 5-azacitiadine.

The overall complete response rate was 38% (7 CR and 3 CRp). Three of 10 responders received prior treatment; 8 of the 10 responders received consolidation. The median (range) of overall survival for the entire patient group was 3.4 months (0.6-28.6) and the median (range) of overall survival for responders was 3.9 months (2.5-28.6).


'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
2. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
3. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
4. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
5. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
6. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
7. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
8. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
9. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
10. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2013)... , Dec. 5, 2013   Omnicell, ... the American Society of Health-System Pharmacists 2013 Mid-Year ... Omnicell,s 2013 theme, "How Far Can You Reach?" ... systems, patient management initiatives that increasingly extend from ... (Logo:  http://photos.prnewswire.com/prnh/20120731/SF48971LOGO-a ) ...
(Date:12/5/2013)... 2013 With patients increasingly searching for medical ... pharmaceuticals are ready for them. Just 28 percent of ... ePharma Competitive Analysis Series were mobile-optimized. ... to mobile. They know it,s a critical channel, but ... Manhattan Research Vice President of Research Monique Levy ...
(Date:12/5/2013)... , December 5, 2013 ... product development services with the introduction of a high ... investment is in response to market demand for high-precision, ... last step in Hovione,s plan to offer development services ... formulation to powder inhalers to final unit dose. ...
Breaking Medicine Technology:Omnicell Expands its Unity Platform to Further Integrate Workflows 2Omnicell Expands its Unity Platform to Further Integrate Workflows 3Omnicell Expands its Unity Platform to Further Integrate Workflows 4Few pharma websites optimized for mobile, according to Manhattan Research's new ePharma Competitive Analysis Series 2Few pharma websites optimized for mobile, according to Manhattan Research's new ePharma Competitive Analysis Series 3Few pharma websites optimized for mobile, according to Manhattan Research's new ePharma Competitive Analysis Series 4Hovione: New Inhalation Capsule Filling Machine Fills Market Gap 2
... , , WARSAW, Ind., Dec. 18 Symmetry Medical Inc. ... products to the global orthopaedic device industry and other medical ... and other staff reductions designed to increase operational efficiency and ... the Company for continued market leadership during the anticipated orthopedic ...
... , ATLANTA, Dec. 18 Patients with overly large ... and those with multiple brain metastases are among those who ... with Leksell Gamma Knife Perfexion systems. The Extend ... to non-invasively fix or immobilize the patient,s head position over ...
Cached Medicine Technology:Symmetry Medical Announces Restructuring 2Symmetry Medical Announces Restructuring 3Symmetry Medical Announces Restructuring 4University of Virginia Acquires New Elekta Technology to Expand Patient Groups That Could Benefit From Gamma Knife Surgery 2University of Virginia Acquires New Elekta Technology to Expand Patient Groups That Could Benefit From Gamma Knife Surgery 3
(Date:12/6/2013)... Continuing Education Company Inc , a Primary ... agenda for the 2nd Annual Primary Care Winter CME ... Maui Resort & Spa on K'aanapali Beach in Hawaii, ... Physician Assistants. The conference is held over five days ... Conference hours are 8am-12:15pm daily. , "Our 2nd Annual ...
(Date:12/6/2013)... FL (PRWEB) December 06, 2013 Adding ... transforming to the dynamic of a household. However, for ... are not always quite as exciting. It is no ... the areas of the chest and abdomen. , ... the post-birth baby weight, neither can restore issues such ...
(Date:12/6/2013)... Rochester, NY (PRWEB) December 06, 2013 ... found a correlation between media coverage and the number ... Center for Advancing Health reports, “The number of adverse ... Centers for Disease Control and Prevention (CDC) and the ... to media coverage and online controversy about the vaccine ...
(Date:12/6/2013)... 2013 The excitement and inspiration of ... in western Colorado comes alive in two new videos ... and river guide Andrew Bishop and New ... recently released short videos about the inclusive team event, ... Area west of Grand Junction in mid-September. , ...
(Date:12/5/2013)... Men who continued to smoke after a cancer ... those who quit smoking after diagnosis, according to a ... , a journal of the American Association for Cancer ... after a cancer diagnosis, those who smoked after diagnosis ... from all causes, after adjusting for factors including age, ...
Breaking Medicine News(10 mins):Health News:Live Primary Care CME (Continuing Medical Education) Faculty and Agenda Announced for Presidents' Week Conference in February 2014 to Be Held in Maui, Hawaii 2Health News:Live Primary Care CME (Continuing Medical Education) Faculty and Agenda Announced for Presidents' Week Conference in February 2014 to Be Held in Maui, Hawaii 3Health News:‘Mommy Makeover’ for Mothers Desiring Their Pre-baby Body Back 2Health News:‘Mommy Makeover’ for Mothers Desiring Their Pre-baby Body Back 3Health News:HPV Vaccine: Is Media Driving Reports of Side Effects?; polyDNA Recommends Gene-Eden-VIR, an HPV Remedy with No Side Effects 2Health News:HPV Vaccine: Is Media Driving Reports of Side Effects?; polyDNA Recommends Gene-Eden-VIR, an HPV Remedy with No Side Effects 3Health News:Two Videos Capture Excitement of World T.E.A.M. Sports’ Annual Adventure TEAM Challenge 2Health News:Two Videos Capture Excitement of World T.E.A.M. Sports’ Annual Adventure TEAM Challenge 3Health News:Cigarette smoking after cancer diagnosis increases risk of death 2
... Reporter , TUESDAY, Dec. 20 (HealthDay News) -- A rise ... risk of dying from heart disease, new research indicates. ... minute to more than 85 beats per minute over 10 ... heart disease compared to people whose heart rates stayed around ...
... don,t lie. But sometimes they may mislead, as in the ... Europe and other parts of the Old World before Christopher ... of this skeletal evidence, including 54 published reports, holds up ... according to an appraisal in the current Yearbook of Physical ...
... --,A hormone called DHEA appears to help ease women,s menopausal ... study says. This is the first evidence that ... adrenal glands, can help sexual function as well as menopausal ... in Italy. The study included 48 postmenopausal women who,d ...
... of Interventional Radiology Foundation,s Discovery Campaign, which seeks ... into new areas of discovery, announced a major ... a provider of imaging and laboratory diagnostic equipment ... to health care customers, pledged $200,000, as a ...
... see color thanks to cone cells, specialized light-sensing neurons located ... The actual light-sensing section of these cells is called the ... stacked discs, each about 30 nanometers (billionths of a meter) ... believe that a better understanding of how and why the ...
... (Boston) - Patricia F. Coogan, ScD, an associate professor ... recently was awarded funding for two grants from the ... grant from the National Institute of Environmental Health Sciences ... hypertension and diabetes in African American women. The second ...
Cached Medicine News:Health News:Jump in Resting Heart Rate Might Signal Higher Death Risk 2Health News:Jump in Resting Heart Rate Might Signal Higher Death Risk 3Health News:Skeletons point to Columbus voyage for syphilis origins 2Health News:Skeletons point to Columbus voyage for syphilis origins 3Health News:Hormone Might Ease Menopause, Boost Women's Sex Life: Study 2Health News:Nanometer-scale growth of cone cells tracked in living human eye 2Health News:Boston University researcher awarded 2 NIH grants 2
... programmable refrigerated floor-standing centrifuge. Mobile space ... large choice of accessories, microprocessor control, ... 4 languages, imbalance detection & shutdown ... dual lid interlock, current and temperature ...
... Compact multi-function refrigerated bench-top centrifuge. ... with AUTO-LOCKreg; JOUAN patented system, ... digital displays, suits all samples, ... detection & shutdown, guard barrier, ...
... bench-top centrifuge. Instant rotor exchange ... patented system, powerful, absolute security, ... label for personalized identification of ... visibility digital displays, suits all ...
... programmable high and low speed refrigerated ... with AUTO-LOCK JOUAN patented system, comprehensive ... security, Lifetime reproducibility, individual password protection ... braking rates (100 run profiles), powerful ...
Medicine Products: